Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Drug Recalls For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Visudyne (verteporfin) Injection, 15 mg, QLT, NDA 21-119/S005 11/25/02 12/9/02 11/26/02 Visudyne (verteporfin) Injection, 15 mg, QLT, NDA 21-119/S004 5/29/02 6/3/02 5/31/02 Visudyne (verteporfin) Injection, 15 mg, QLT, NDA 21-119/S003 4/30/02 5/2/02 5/1/02 Visudyne (verteporfin) Injection, 15 mg, QLT, NDA 21-119/S001 8/22/01 11/6/01 11/6/01 12/12/01 Visudyne (verteporfin) Injection, 15 mg, QLT Photo Therapeutics NDA 21-119 4/12/00 4/17/00 4/17/00 12/11/01 Visudyne Indications: for the treatment of age-related macular degeneration in patients with predominantly classic subfoveal choroidal neovascularization. Visudyne (verteporfin) Injection, QLT, Inc. | Visudyne (verteporfin for injection), QLT Inc., Labeling Revision | Visudyne (verteporfin) Injection, QLT Inc., Labeling Revision | Visudyne (verteporfin) Injection, QLT, Inc., Efficacy Supplement with Clinical Data to Support ^ FDA's latest approval appears at the bottom of this list. ^   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News © 2008 Betterchem.com